Absstract of: US2023025108A1

Described herein are diagnostic and control fusion protein reagents and methods for use thereof in simple rapid and inexpensive hemagglutinin assays for the detection of subject antibodies directed to the SARS-CoV-2 virus.

Absstract of: US2023022162A1

A method of treatment for coronavirus disease 2019 (COVID-19) is disclosed herein. The method comprises administering a therapeutically effective dose of a combination of ribavirin and minocycline. A pharmaceutical composition comprising ribavirin and minocycline is also disclosed herein. The pharmaceutical composition may further include one or more pharmaceutical excipients.

Absstract of: US2023022109A1

Provided is a novel coronavirus vaccine using replication-deficient human type 5 adenovirus as a vector. The vaccine takes the replication-deficient human type 5 adenovirus that is lack of E1 and E3 in a combined mode as a vector, and HEK293 cells that integrate adenovirus E1 genes serve as a packaging cell line, and protective antigenic genes carried are optimized COVID-19 (SARS-CoV-2) S protein genes (Ad5-nCoV). The vaccine has good immunogenicity in both mouse and guinea pig models and can induce the body to produce a strong cellular and humoral immune responses in a short time. Research on the protective effect of hACE2 transgenic mice shows that 14 days after a single Ad5-nCoV immunization, the viral load in lung tissues can be significantly reduced. It shows that the vaccine has a good immune protection effect against COVID-19.

Absstract of: US2023021431A1

This disclosure relates to novel SARS-CoV-2 targeting sequences. Novel SARS-CoV-2 targeting oligonucleotides for the treatment of SARS-CoV-2 infection are also provided.

Absstract of: US2023022696A1

This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a quinoline or thioxanthenone (or similar) structure which function as autophagy inhibitors and/or histone deactylase inhibitors, and their use as therapeutics for the treatment of conditions characterized with aberrant autophagy activity and/or aberrant HDAC activity (e.g., cancer, pulmonary hypertension, diabetes, neurodegenerative disorders, aging, heart disease, rheumatoid arthritis, infectious diseases, conditions and symptoms caused by a viral infection (e.g., COVID-19)).

Absstract of: WO2023001549A1

The present invention relates to a system for assisting with provision of diagnostic information, especially with a view to detecting a disease in a person, especially a contagious disease such as COVID-19, this detecting system comprising: - a device for acquiring examination data on the person, this acquiring device comprising at least two sensors for measuring a given physiological measurement, such as a radar and a thermal camera, to acquire these examination data, these sensors especially being arranged to work without contact with the person, - a data-processing device arranged to receive these data obtained by the sensors of the acquiring device, this processing device further being arranged to fuse data delivered at least by the two sensors of the acquiring device especially with a view to increasing the robustness of the examination data acquired on the person.

Absstract of: WO2023002409A1

Provided herein are compounds and compositions for treating, managing or preventing coronaviral related diseases. In particular, provided herein are compounds which are inhibitors of SARS-CoV-2 main protease (Mpro), pharmaceutical compositions comprising such compounds, method for synthesizing such compounds and methods of using such compounds and compositions for the treatment, management or prevention of coronaviral related diseases.

Absstract of: GB2609040A

A process for preparing a cellulose-containing microporous superabsorbent composition includes comminuting dry granulated herbaceous plant material, e.g. sugar beet, orange peel or apple residue, to form microparticles having an average particle diameter from 100μm to 800μm. Preferably the method includes contacting the microparticles with an aqueous alkaline solution, neutralising and/or washing the mixture, removing fluids from the mixture, and drying the obtained material. The starting material may comprise less than 20wt.% lignin. The superabsorbent composition may have a water absorption capacity (WAC) in the range of from 2 to 10. The cellulosic superabsorbent composition may be a material which comprises a fluid-superabsorbent volume area able to absorb 3-6 times of the original weight within 30 seconds, and may exhibit a virucidal activity as expressed by a reduction in viral titre of influenza A and/or human coronavirus of above 90% as determined pursuant to ISO18184:2019. The material may be in the form of a medical, surgical, sanitary or protective article, e.g. a dressing, pad, tampon, gown, glove etc, a packaging material or a particulate absorbent for spills. An antimicrobial or other functional agent may be adhered to the material to form a functionalised superabsorbent composition.

Absstract of: EP4122461A1

The invention relates to a pharmaceutical composition that is appropriate to treat or prevent SARS-CoV-2-related diseases such as COVID-19. The pharmaceutical composition comprises a pharmaceutically effective amount of i) otamixaban or a pharmaceutically acceptable salt thereof and ii) at least one of camostat, a pharmaceutically acceptable salt of camostat, nafamostat, and a pharmaceutically acceptable salt of nafamostat.

Absstract of: WO2023287875A1

The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections).

Absstract of: AU2021266428A1

A diagnostic device (1) for detecting a first member of a reporter-analyte pair. The diagnostic device comprises an inlet for receiving a liquid, biological sample and a porous membrane element (10) comprising a detection portion. The detection portion is in liquid communication with the inlet and a second member of the reporter-analyte pair is immobilised on the detection portion. One of the first or second member of the reporter-analyte pair comprises a biological antigen and the other of the first or second member of the reporter-analyte pair comprises an antibody specific for the biological antigen. The biological antigen comprises a spike protein, or a fragment thereof, of COVID-19. The device is for independent detection of the spike protein, or the fragment thereof, or of an antibody specific for the spike protein, or the fragment thereof, in the biological sample.

Absstract of: WO2023285654A2

The present invention relates to compounds for the treatment of a SARS-CoV-2 infection and/or COVID-19 in a subject.

Absstract of: WO2023287403A1

A nasal spray solution of the present invention includes a Povidone iodine solution; a Vitamin D liquid, Polysorbate 80nf, Xylitol NF, water sterile, Sodium hydroxide 10% solution, and Polysaccharide 1% solution, wherein 1% solution further includes a gellan gum and a carrageenan, used as carriers to deliver liquids to cells of human and act as entrapment within a polymeric coating to block virus uptake into the cells, inactivate the virus, and protect a lining of an upper respiratory pathways against COVID-19 and SARS.

Absstract of: WO2023287870A2

This application relates to methods for assessing patients suffering from coronavirus infection as responders or a non-responders to an immunomodulating therapy, and methods of treating said subjects.

Absstract of: WO2023284687A1

A biosensing detection method and a detection system for a neutralization antibody. The detection method comprises taking biotinylated hACE2 (2) as an antigen and immobilizing same to a surface of a streptavidin chip to obtain a streptavidin optical fiber (1) probe, and using a SARS-CoV-2 neutralization antibody (3), a conjugate HRP-RBD (4) and a signal amplifying agent DAB (5). On the basis of an optical fiber biolayer interference technique combined with effective signal amplification, the rapid, high-sensitivity, simple, convenient and quantifiable detection method and detection system are established and used, for example, for detecting a SARS-CoV-2 neutralization antibody in human serum and detecting a SARS-CoV-2 neutralization antibody in a whole blood sample, which is obtained by using a dried blood spot sampling method.

Absstract of: WO2023284686A1

A biosensing detection method and system for binding antibodies. On the basis of optical fiber biolayer interferometry, and in combination with effective signal amplification, a quick, high-sensitivity, simple, and quantitative full-automatic optical biosensing detection method and system are established, which can be used for the detection of COVID-19 binding antibodies in human serum and the detection of COVID-19 binding antibodies in a whole blood sample obtained by means of a dry blood spot sampling method.

Absstract of: WO2023284514A1

Disclosed in the present invention is an ultrasensitive antibody detection method, in particular an ultrasensitive detection method for SARS-CoV-2 antibodies. Also provided in the present invention are crRNA, a probe, a conjugate, a combination product, a test strip, a test kit, etc. used for the method, which can be used to detect antibodies produced by immune responses caused by antigens in the body. The sensitivity is very high, the detection limit can be as low as 1aM, operation is simple, and no washing step is needed.

Absstract of: WO2023283831A1

Disclosed in the present invention is a compound having an inhibitory effect on a virus main protease (3CL protease, Mpro), which also has a significant inhibitory activity on the Mpros of SARS coronavirus (SARS-CoV) and novel coronavirus (SARS-Cov-2). Further disclosed in the present invention is an application of a pharmaceutical composition containing such a compound or a pharmaceutically acceptable salt of the pharmaceutical composition in the preparation, prevention and/or treatment of virus Mpro-associated diseases, for example, in the treatment of novel coronavirus (SARS-Cov-2)-associated diseases.

Absstract of: WO2023287901A1

The invention provides compositions, devices, methods and kits allowing for rapid diagnosis of infectious diseases, including viruses, such as influenza and SARS-CoV-2, via extraction-free, direct PCR techniques using combined biological samples, such as a saliva sample and respiratory mucosa sample in a buffer composition comprising nuclease-free water, an antifungal, an antibiotic, and a ribonuclease inhibitor.

Absstract of: WO2023287815A1

Disclosed are methods for assessing the severity of a coronavirus infection through the measurement of caspase 4 and methods of treating a coronavirus infection comprising administering to an infected subject an inhibitor of CASP4 or its downstream effectors IL-1 B, Cxcl1, or Willebrand factor (vWF). The coronaviral infection may be a SARS-CoV-2 variant.

Absstract of: WO2023287889A1

An example biosensor includes a substrate, a graphene layer disposed on the substrate, and a binding site bonded to the graphene. The binding site includes an antibody configured to bind a SARS-CoV-2 spike glycoprotein. The biosensor can be configured to detect the SARS-CoV-2 spike protein in at least one of a saliva sample or a blood sample.

Absstract of: WO2023288078A1

This application provides compositions and methods for treating, preventing, or reducing the progression rate and/or severity of COVID-19, particularly treating, preventing or reducing the progression rate and/or severity of one or more COVID-19-associated complications.

Absstract of: WO2023285898A1

An artificial intelligence-based system and method for scalable screening of individuals for respiratory infection, such as COVID-19. The system is trained to distinguish distinct latent features of cough sounds produced by a COVID-19 infected person from cough sounds produced by patients suffering from any other respiratory infection or involuntary cough sounds produced by a healthy person. Cough sound samples from individuals can be remotely collected and evaluated by the system for likelihood of the COVID-19 infection. Additionally, images of affected body parts, biomarkers, metadata, and other respiratory sound samples can also be used for screening.

Absstract of: WO2023284476A1

A novel SARS-CoV-2 antibody detection test strip, which comprises: a base board (70), a detection membrane (50), a sample pad (10), a gold-labeled pad (20), and an absorbent pad (60); test lines (30) and a control line (40) are arranged in parallel on the detection membrane (50); there are at least two test lines (30), and the test lines (30) and the gold-labeled pad (20) are fixedly provided with proteins that jointly detect antibodies of SARS-CoV-2. The present antibody detection test strip intuitively displays antibody types for different antigen proteins in a human body, and analysis of different immunity circumstances can be facilitated.

Absstract of: WO2023284254A1

Provided are a construction method for and an application of an hACE2 humanized transgenic pig. Using CRISPR-Cas9 gene editing technology, a pig's own ACE2 gene is replaced with hACE2 cDNA, which can avoid the problem of pig endogenous ACE2 being expressed simultaneously while human ACE2 is expressed. The hACE2 humanized pig model is an ideal large animal pig model capable of mimicking the clinical symptoms and therapeutic responses of human COVID-19, and can be used for research into SARS-CoV-2 infection and pathogenesis, and for the development and testing of diagnostic technologies, antiviral therapies and vaccines, and the evaluation of the efficacy and safety of candidate drugs.